To draw attention to this subject, I have made several of these articles available as free downloads on our website. The first of these articles is from Tudor Oprea and colleagues on the topic of “Drug repurposing from an academic perspective” (Drug Discovery Today: Therapeutic Strategies (2011), 8 (3/4), 61-69) they summarize the current project status for several drugs or classes of drugs, including: raltegravir, cyclobenzaprine, benzbromarone, mometasone furoate, astemizole, R-naproxen, ketorolac, tolfenamic acid, phenothiazines, methylergonovine maleate and beta-adrenergic receptor drugs. Furthermore, they discuss the strengths and weaknesses of academic-based drug repurposing research. The authors suggest that the development of a more streamlined regulatory process worldwide, and the development of precompetitive knowledge transfer systems such as a global healthcare database focused on regulatory and scientific information for drugs worldwide, are among the potential approaches that may improve the process of academic drug discovery and repurposing.